CATX logo

PERSPECTIVE THERAPEUTICS INC

CATXNYSE AMERICAN
πŸ† #3787 by market capEarnings Nov 9US Equity
$1.25β–² $0.06 (+5.06%)
Pre-market Β· at close
πŸ””
Track CATX
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 5.1%
7dβ–Ό 44.5%
14dβ–Ό 46.9%
30dβ–Ό 52.5%
ytdβ–Ό 54.7%
1yβ–Ό 54.4%
🏦Market Cap
$142M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-100.0%
Declining
πŸ“ŠGross Margin
-419.4%
Thin
πŸ’΅FCF Margin
-33111.2%
Thin
βš–οΈP/S Ratio
389.9x
Expensive
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$1.07 – $1.25
52-Week Range
$1.06 – $6.16
Volume (shares)
325,734
Avg Volume (shares)
β€”
Shares Outstanding
114.2M
Next Earnings
2026-11-09

Fundamentals Snapshot

Annual Revenue
β€”
Last Q Revenue
$81,000
P/E Ratio
-0.8
P/S Ratio
389.9x
EPS (TTM)
$-1.58
Dividend Yield
0.00%
Dilution (1yr)
+5.2%
CATX logo

PERSPECTIVE THERAPEUTICS INC

CATX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0β–Ό βˆ’100.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
-58.6%β–Ό βˆ’158.6% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$114Mβ–² +70.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$95Mβ–² +31.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
74.3Mβ–² +5.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$27Mβ–Ό βˆ’$30M YoY
StockOtter Β· stockotter.space

About PERSPECTIVE THERAPEUTICS INC

Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100

Analyst Ratings

β“˜
Consensus
Buy
21 analysts
Strong Buy5
Buy14
Hold2
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.